Widely-used hormone drug associated with increased risk of benign brain tumour at high doses

High doses of a widely-used drug used in the hormonal treatment of conditions such as excessive hair growth, early puberty, prostate cancer are linked to an increased risk of meningioma — the most common type of benign brain tumour, finds a University of Bristol-led study of over 8-million patients. The study is published in Scientific Reports today [Friday 4 Feb 2022].